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Orthotopic liver transplantation was performed 15 months 
to 20 years ago in 126 recipients, all of whom were under 18 
years of age. Eighty-six of these pediatric recipients were 
treated before 1980 with azathioprine (or cyclophospham-
ide) and prednisone, to which antilymphocyte globulin 
(ALG) usually was added. One-year patient survival was 
40%. In the last 40 cases, the new drug cyclosporine has 
been given with low doses of steroids. The one-year patient 
survival increased to 6S %. Both in the pre-cyclosporine era 
and more recently, the survival of patients with biliary 
atresia has been lower than in the next largest category of 
patients, namely, those with liver-based inborn metabolic 
errors. The difficulty of operation in patients with biliary 
atresia has been greater than in recipients with other 
diagnoses, partly because of previous operations such as 
portoenterostomy (Kasai procedure). Hepatic portoenter-
ostomy, worthwhile as it is, has posed technical difficulties 
for eventual liver transplantation, particularly when com-
plicated Roux limb techniques or venting procedures have 
been applied. In our total experience the longest survival 
after liver replacement in a child whose original diagnosis 
was biliary atresia is 13% years. 
Although hepatic portoenterostomy is the first op-
eration to be performed on children with biliary 
atresia [1], the majority of such Kasai procedures 
fail, leaving hepatic transplantation as the only 
option. The use of liver transplantation in infants 
and children has been questioned because of the 
high morbidity and mortality rates. Even after 
"successful" transplantation, the quality of life has 
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been too often degraded by the side effects of high-
dose steroid therapy. 
We report here the recent progress in liver trans-
plantation in infants and children that has been 
made possible with the new immunosuppressive 
drug regimen of cyclosporine and low-dose ste-
roids. The results have been compared to those 
obtained in the past with conventional immunosup-
pression. The special focus in this communication 
will be on the subgroup of pediatric recipients who 
had biliary atresia. 
Materials and Methods 
The first human liver transplantations were per-
formed in 1963 [2]. Since then we have attempted 
more than 300 liver replacements, first at the Uni-
versity of Colorado and since 1981 at the University 
of Pittsburgh. The first 170 patients were treated 
before March, 1980, with the "conventional" im-
munosuppressive regimen of azathioprine (or cyclo-
phosphamide), prednisone, and usually antilympho-
cyte globulin (ALG) [3]. Since March, 1980, liver 
allograft recipients were treated with a new immu-
nosuppressive regimen of cyclosporine and predni-
sone [3, 4]. Steroids are a necessary addition to 
cYclosporine to achieve adequate immunosuppres-
sion, but the doses used are much less than those 
required when given with azathioprine. 
Among the 170 patients given conventional im-
munosuppressive therapy, 86 were pediatric recipi-
ents who were age 18 or under. Of 100 consecutive 
liver recipients under cyc1osporine-steroid therapy 
between March, 1980, and December, 1982, forty 
were pediatric recipients. 
Indications for Liver Transplantation 
The reasons for liver transplantation in pediatric 
patients are listed in Table 1. Patients with biliary 
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Table 1. Indications for transplantation in pediatric patients (;;:'18 years). 
Precyclosporine era Cyclosporine era 
(before 1980) (after 1980) Total 
Number Number number 
-----
Biliary atresia and hypoplasia 51 20 71 
Inborn metabolic errors 13a l()d 23 
Chronic aggressive hepatitis 13 3 16 
Hepatoma 3b ()e 3 
Neonatal hepatitis 2 I 3 
Congenital hepatic fibrosis 2 0 2 
Secondary biliary cirrhosis 2c If 3 
Byler's disease 0 3K 3 
Budd-Chiari syndrome 0 I 1 
Cellular inflammatory pseudotumor 0 1 I 
Total 86 40 126 
ainborn errors: Alpha-I-antitrypsin deficiency (9); Wilson's disease (2); Tyrosinemia (1); Type IV glycogen storage 
disease (1). 
bFive other patients had incidental malignancies (4 hepatomas and I hepatoblastoma) in their excised liver. The 
principal diagnoses in these 5 cases were biliary atresia (3 examples), alpha-I-antitrypsin deficiency (1 example), and 
congenital tyrosinemia (l example). The diagnosis of the neoplastic change was known in advance only in 2 ofthe 5 cases. 
cSecondary to trauma or choledochal cyst (one each). 
dlnborn errors: Alpha-I-antitrypsin deficiency (6); Wilson's disease (1); Tyrosinemia 0); Type I glycogen storage 
disease 0); Sea-blue histiocyte syndrome (1). 
'Two patients had incidental hepatomas: one with tyrosinemia, another with sea-blue histiocyte syndrome. 
iSecondary to choledochal cyst. 
gDiagnosis equivocal in one case. 
atresia or hypoplasia accounted for 71 of the 126 
total pediatric liver recipients. Almost all had failed 
hepatic portoenterostomy. The second largest re-
cipient group was made up of several inborn errors 
of metabolism, including alpha-I-antitrypsin defi-
ciency disease, Wilson's disease, tyrosinemia, gly-
cogen storage disease, and the sea blue histiocyte 
syndrome. 
Donor Operation 
The liver, heart, and both kidneys can be procured 
from a single donor without compromising the 
anatomy and effective preservation of any of the 
organs [5]. In an infant or child whose liver is being 
removed, it is often advisable to keep the celiac axis 
in continuity with the upper abdominal and thoracic 
aorta. The donor thoracic aorta can be turned down 
1800 for anastomosis to the recipient's lower ab-
dominal aorta. The use of the aortic anastomotic 
technique is particularly valuable when the liver 
graft receives part of its blood supply from the 
superior mesenteric artery; then both the celiac axis 
and the superior mesenteric artery can be vascular-
ized via the single aortic anastomosis [6, 7]. 
Recipient Operation 
The techniques of orthothopic liver transplantation 
have become well standardized [2, 3,6, 7]. 
In infants and young children, a bilateral subcos-
tal incision or upper abdominal transverse incision 
using the previous incision (when present) gives 
adequate exposure. Recipient hepatectomy in chil-
dren is generally easier than in adults. On the other 
hand, the vascular anastomoses (particularly of the 
artery and portal vein) and biliary reconstruction 
are more difficult, or at least more sophisticated, in 
pediatric recipients than in adults. 
We employ a continuous suture using monofila-
ment polypropylene (Prolene®) for all vascular 
anastomoses. To avoid the purse-stringing that can 
easily occur with this technique, care is taken to 
prevent undue traction on the sutures. When the 
sutures are completed, the knots are placed away 
from the vessel wall in order to leave extra Prolene® 
which slowly works its way back into the suture 
line. This "growth factor" technique [8] is an 
important means of eliminating strictures in small-
calibre anastomoses. 
The ideal form of biliary duct reconstruction is a 
choledochocholedochostomy with aT-tube stent, 
but in patients with biliary atresia, that option does 
not exist. Cholecystoenterostomy, which depends 
on bile drainage through the cystic duct, is not used 
because of the high incidence of subsequent 
obstruction of the cystic duct [3, 9]. End-to-side 
anastomosis of graft common duct to a Roux-en-Y 
loop of jejunum with an internal stent (choledocho-
jejunostomy) has been the reconstruction of choice 
in cases of biliary atresia and for other disorders in 
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which the recipient common duct is inadequate; it 
has proven to be one of the most satisfactory of all 
the methods of biliary reconstruction [9]. 
In patients with biliary atresia, the Roux limb 
construction for hepatic portoenterostomy can be 
reused at the time of liver transplantation providing 
the limb is not irreparably damaged during the hilar 
dissection of recipient hepatectomy. The risk of 
Roux limb injury has been great when skin jejunos-
tomy has been used with the Kasai procedure in 
hopes of decreasing cholangitis. Even if the ostomy 
had been closed by the time of transplantation, this 
portion of the Roux limb frequently has to be 
resected, and often with great difficulty. 
Results 
Causes of Death 
Fifty-three of the 86 pediatric liver recipients be-
tween 1963 and early 1980 and 14 of the 40 between 
March, 1980, and December, 1982, died within a 
year after transplantation. Although the causes of 
death in these patients were usually multiple, a 
single most important factor was selected in each 
case (Table 2). 
During the precyclosporine era, bacterial, fungal, 
and viral infections were the main cause of death 
within a year after transplantation (20 of 53 deaths). 
There were 9 deaths from abdominal sepsis, 5 from 
viral infection (adenovirus, chickenpox, and her-
pes), 4 from systemic bacterial and fungal sepsis, 
and 2 from pulmonary infection. Although infec-
tious complications continue to be a major threat to 
life after transplantation, none of the 14 deaths 
under cyclosporine therapy was thought to have 
been primarily from infection. 
Significant numbers of deaths were caused by 
surgical technical complications of arterial, venous, 
or biliary anastomoses. In the precyclosporine era, 
there were 15 deaths in this category. Eight of the 
15 were failures in biliary duct reconstruction, 4 in 
hepatic artery anastomosis, 3 in portal vein anasto-
mosis, and 1 in the suprahepatic inferior vena caval 
anastomosis. In the cyclosporine era, surgical tech-
nical complications were the most frequent direct 
cause of death (7 of 14). There were 3 failures in 
hepatic artery anastomosis, and one each of the 
hepatic artery anastomosis, the portal venous anas-
tomosis, the suprahepatic vena caval anastomosis, 
and biliary duct reconstruction. 
Acute or chronic rejection was the third main 
cause of death in the precyclosporine era, and the 
second most common cause in the cyclosporine era 
(Table 2). Despite better immunosuppression and 
improved survival with cyclosporine, approximate-
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Table 2. Main causes of death within a year after liver 
transplantation among 86 children in precyclosporine era 
and 40 children in cyclosporine era. 
Precyclo- Cyclosporine 
sporine era era 
(86 children) (40 children) 
Intra- and Perioperative 
death 3 
Surgical technical 
complication 15 7 
Unsatisfactory liver graft 3 1 
Graft rejection 9 4 
Infection 20 0 
Recurrent malignancy 1 0 
Other 2a I b 
Total 53 14 
aOne died from pulmonary emboli at 52 days and 
another from respiratory insufficiency due to an over-
sized graft. 
bOne died from graft hypoxia due to marked pulmonary 
arteriovenous shunt. 
ly 10% ofliver graft recipients died from rejection in 
both the precyclosporine era and the cyclosporine 
era. 
Survival 
The 2-year actual survival of 86 pediatric recipients 
in the precyclosporine era and actuarial survival of 
40 pediatric recipients in the cyclosporine era are 
shown in Fig. 1. The shortest follow-up period in 
the cyclosporine-treated group is 12 months, and 
the longest is more than 3 years. After the introduc-
tion of cyclosporine, the I-year survival after liver 
transplantation improved from 40% to 65%. 
The influence of original liver disease on survival 
was analyzed for the 2 most common indications for 
transplantation (biliary atresia and inborn metabolic 
errors) in the precyclosporine and cyclosporine eras 
(Figs. 2, 3). The survival of children with biliary 
atresia was substantially lower than overall survival 
in the precyclosporine era (Fig. 2), but it was only 
slightly worse than the overall survival in the cyclo-
sporine era (Fig. 3). The survival of children with 
biliary atresia was inferior to that of children with 
inborn metabolic errors during both the early and 
later phases of our experience. 
The influence of age at the time of liver transplan-
tation on survival was studied. In the precyclospor-
ine era, 28 (53%) of 53 infants and preschool chil-
dren (less than 6 years), 8 (50%) of 16 school age 
children (between 6 and 12 years), and 13 (76%) of 
17 adolescents lived more than 3 months (Fig. 4). In 
the cyclosporine era, 16 (76%) of 21 infants and 
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Fig. 1. A comparison of survival after liver transplanta-
tion between 86 pediatric liver recipients under conven-
tional immunosuppressive therapy (see text for descrip-
tion) and 40 pediatric recipients under cyclosporine-
prednisone therapy. 
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Fig. 2. Influence of original liver disease on 
survival under conventional immunosuppression. 
I-year 
preschool children, 8 (67%) of 12 school age chil-
dren, and 6 (86%) of7 adolescents lived more than 3 
months (Fig. 4). Thus, the 3-month survival of 
infants and preschool children was similar to that of 
school age children both in the precyclosporine era 
and in the cyclosporine era. It is noteworthy that 5 
(71 %) of 7 infants less than a year old lived more 
than 3 months. The technical difficulties of liver 
transplantation in infants have been fairly well 
overcome. The age of children should not be a 
consideration in accepting them as candidates for 
liver transplantation, although liver donors for in-
fants are scarce. 
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survival under cyclosporine-steroid therapy. 
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Fig. 4. Age distribution of 126 pediatric liver recipients. A 
shaded square represents a child who survived more than 
3 months. and a black square represents a child who died 
within 3 months. All of the surviving patients treated with 
cyclosporine have follow-ups of at least 15 months. 
Discussion 
Despite the continued efforts over the last 2 decades 
to improve the survival and the quality of life after 
liver transplantation, real progress had to await the 
discovery [10] and clinical use [4, Il, 12] of cyclo-
sporine. In combination with low-dose steroids, 
cyclosporine provides more effective and safer im-
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munosuppression than conventional double or tri-
ple drug therapy [4, 12]. With this new immu~osup­
pressive agent, the results after transplantatlOn of 
kidneys, liver, and heart have improved. 
In pediatric liver transplantation, the I-year sur-
vival improved from 40% to 65% with cyclosporine 
and low-dose steroid therapy. Infectious complica-
tions, which had been the most common direct 
cause of death after liver transplantation, became 
less frequent and more treatable. The absence of 
significant morbidity has been remarkable [12]. The 
complications of high-dose steroids, such as growth 
retardation, Cushingoid features, and bone disease 
that plagued efforts at pediatric transplantation, 
have been virtually eliminated. 
Survival after liver transplantation of children 
with biliary atresia has been inferior to that of 
children with liver-based inborn metabolic errors in 
both the precyclosporine era and the cyclosporine 
era. This is partly due to the fact that previous 
major procedures such as hepatic portoenterostomy 
make the transplant operation more difficult. In 
addition, anatomical anomalies, such as hypoplas-
tic, sclerotic, and sometimes thrombosed portal 
veins are more common in children with advanced 
biliary atresia [3, 6]. However, in the cyclosporine 
era the survival rate of children who undergo liver 
transplantation for biliary atresia has increased al-
most to the level of overall survival in the pediatric 
cases as a whole. 
The contention that infants and small children are 
not good candidates for liver transplantation be-
cause of age and small size has been proven incor-
rect. The opinion that the quality of life will be 
substandard has been held only by those who have 
not seen these infants and children at play. 
Resume 
La transplantation orthotopique du foie a ete prati-
quee (depuis 25 ans jusqu'a 15 mois) chez 126 sujets 
ages de moins de 18 ans. Quatre-vingt-six de ces 
sujetsjeunes ont ete traites avant 1980 par l'azathio-
prine (ou cyclophosphamide) et la prednisone ainsi 
que generalement par la globuline antilymphocy-
taire. La survie a un an fut de 40%. Dans les 40 
dernieres transplantations un nouvel agent, la cy-
closporine, fut employe simultanement avec de 
faibles doses de stero'ides. Le taux de survie a un an 
s'est eleve jusqu'a 65%. 
Aussi bien au cours de la premiere periode que 
lors de la seconde, Ie taux de survie des enfants qui 
ont subi une transplantation pour atn!sie biliaire a 
ete inferieur a celui de ceux qui ont ete l'objet d'une 
transplantation pour des affections metaboliques 
hepatiques du nouveau-ne. La difficulte de l'opera-
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tion chez les sujets atteints d'atresie biliaire resulte 
du fait que la transplantation est effectuee tres 
souvent apres echec de la porto-enterostomie ou 
operation de Kasai, de la presence d'une anse 
jejunale montee en Y ou d'un ventousage. Le 
meilleur resultat des transplantations hepatiques 
pour atresie biliaire que nous avons pratiquees 
repond a une survie de 13 ans et 8 mois. 
Resumen 
EI transplante ortotopico de hfgado fue realizado en 
126 recipientes con edades menores de 18 anos, en 
el perfodo comprendido entre los pasados 15 meses 
a 20 anos. Ochenta y seis de estos recipientes 
pediatricos fueron tratados con anterioridad a 1980 
con azatioprina (0 ciclofosfamida) y prednisona, a 
10 cual generalmente se aiiadio globulina antilinfod-
tic a (ALG). La supervivencia a un ano fue de 40%. 
En los ultimos 40 casos se ha administrado la nueva 
droga ciclosporina, junto con dosis bqjas de este-
roides. La supervivencia a un ano aumento a 65%. 
Tanto en la era preciclosporina como en la epoca 
reciente, la supervivencia de los pacientes con 
atresia biliar ha sido mas baja que la de los pa-
cientes de la siguiente categoria mayor, constitufda 
por aquellos con defectos metabolicos congenitos 
del hfgado. La dificultad operatoria en los pacientes 
con atresia biliar ha sido mayor que en los pacientes 
con otros diagnosticos, en parte debido a opera-
ciones previas tales como portoenterostomfas (pro-
cedimiento de Kasai). La portoenterostomia hepati-
ca, siendo un procedimiento valioso, ha presentado 
dificultades en cuanto a un transplante hepatico 
eventual, especialmente cuando se han empleado 
tecnicas de anastomosis de Roux-en-Y 0 procedi-
mientos de descompresion. La supervivencia mas 
prolongada despues del reemplazo hepatico en 
nuestra experiencia es de casi 14 anos, en un nino 
cuyo diagnostico original era atresia biliar. 
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